Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05515406 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

A Phase 1 study of Lymphoma, Non-Hodgkin and Leukemia, Lymphocytic, Chronic, B-Cell, sponsored by Ono Pharmaceutical Co..

Active
Registry status
Phase 1
Development phase
108
Enrollment target
10
Study locations

NCT05515406 is a Phase 1 study of Lymphoma, Non-Hodgkin and Leukemia, Lymphocytic, Chronic, B-Cell that is active but no longer recruiting, run by Ono Pharmaceutical Co.. The registered enrollment target is 108 participants, below the 392-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (72% lower). The trial reports 10 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05515406, a Phase 1 study of Lymphoma, Non-Hodgkin and Leukemia, Lymphocytic, Chronic, B-Cell, is active but no longer recruiting, sponsored by Ono Pharmaceutical Co..

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
108 participants
Enrollment target
10
Study locations

Study Summary

This is a Phase 1, open-label, multicenter study. This will be the first-in-human clinical study for ONO-7018 and will be conducted in two phases: a Dose Escalation Phase (Part 1) and a Dose Expansion Phase (Part 2).

Conditions Studied

Lymphoma, Non-Hodgkin Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

  • DRUG ONO-7018

Study Locations (10)

Pennsylvania

  • University of Pennsylvania - Philadelphia
  • Thomas Jefferson University - Philadelphia

Texas

  • Baylor Scott & White Research Institute - Dallas
  • MD Anderson Cancer Center - Houston

California

  • Jonsson Comprehensive Cancer Center - Santa Monica

Missouri

  • AMR Kansas City - Kansas City

North Carolina

  • Leo Jenkins Cancer Center/ECU School of Medicine - Greenville

Ohio

  • University of Cincinnati - Cincinnati

Tennessee

  • Sarah Cannon Research Institute - Nashville

Washington

  • Northwest Medical Specialities - Tacoma

Trial Details

FieldValue
Enrollment Target 108 participants
Start Date 2023-02-13
Est. Completion 2027-12
Phase Phase 1

Sponsor

Ono Pharmaceutical Co.

17 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05515406

The ClinicalTrials.gov registry entry for NCT05515406 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 392-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (72% lower). The listed sponsor is Ono Pharmaceutical Co., which has 17 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 1 intervention - of which ONO-7018 is the first listed.

NCT05515406 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Pennsylvania, Texas, California.

Frequently Asked Questions

What is clinical trial NCT05515406 about?

NCT05515406 is a clinical study titled "A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL". This is a Phase 1, open-label, multicenter study. This will be the first-in-human clinical study for ONO-7018 and will be conducted in two phases: a Dose Escalation Phase (Part 1) and a Dose Expansion Phase (Part 2).

What is the current status of trial NCT05515406?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2023-02-13. Estimated completion is 2027-12.

What conditions does trial NCT05515406 study?

This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell.

What interventions are being tested in trial NCT05515406?

The interventions under investigation include: ONO-7018 (DRUG).

Who is sponsoring clinical trial NCT05515406?

This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05515406 being conducted?

This trial has 10 study locations across California, Missouri, North Carolina, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma, Non-Hodgkin

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma, Non-Hodgkin

All registered trials for this condition

Leukemia, Lymphocytic, Chronic, B-Cell

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.